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ABSTRACT
Introduction Calcium dobesilate (CaD) has been used 
in the treatment of diabetic retinopathy (DR) due to its 
potential in protecting against retinal vascular damage. 
However, there is limited evidence exploring its efficacy 
in combating DR progression. This study is aimed at 
evaluating whether CaD could prevent DR progression into 
an advanced stage among Chinese patients with mild- to- 
moderate non- proliferative DR (NPDR).
Methods and analysis This study is a single- blind, 
multicentre, cluster- randomised, controlled superiority 
trial. A total of 1272 patients with mild- to- moderate NPDR 
will be enrolled and randomly assigned at a 1:1 ratio into 
the control group (conventional treatment group) and 
the intervention group (conventional treatment plus CaD 
(500 mg three times per day) for 12 months). Patients will 
be followed at 1, 3, 6 and 12 months after randomisation 
and receiving treatments, with the severity of DR assessed 
by the Early Treatment Diabetic Retinopathy Study (ETDRS) 
scale. The primary endpoint is the progression of DR 
during follow- up, which is defined as an increase of two or 
more steps in the ETDRS scale. The secondary endpoints 
include the concomitant changes in visual acuity, 
presence, number, location and type of retinal lesions, and 
retinal blood vessel diameter as well as the arteriovenous 
ratio at different visits.
Ethics and dissemination Each local ethics committee 
(first Vote: Ethical Review Committees of Zhongda Hospital 
of Southeast University (2019ZDSYLL132- P01)) has 
approved the study. The results will be published in high 
impact peer- reviewed scientific journals aimed at the 
general reader.
Trial registration numbers NCT04283162.
INTRODUCTION
Diabetic retinopathy (DR) is a common 
microvascular complication associated with 
diabetes, and encompasses a broad clinical 
spectrum from the mild non- proliferative 
DR (NPDR) to a more advanced stage of 
vision- threatening such as proliferative DR 
(PDR) and diabetic macular oedema (DME).1 
The pathogenesis of DR involves a variety of 
abnormal pathways, which are triggered by a 
series of factors including chronic hypergly-
caemic, free radicals, advanced glycosylation 
end products, inflammatory cytokines and 
vascular endothelial growth factors (VEGF).2 
These may eventually lead to blood- retinal 
barrier (BRB) breakdown, retinal neovascu-
larisation and retinal neuronal apoptosis,3 
with BRB injury being considered the hall-
mark of DR.4
There is evidence that 30%–50% of 
patients with diabetes may develop vision- 
threatening retinopathy during their life-
time.5 Timely intervention, such as intensive 
diabetes management, adjunctive anti- VEGF 
therapy, laser photocoagulation and surgical 
management, can prevent up to 98% of the 
cases developing vision loss.1 However, tight 
Strengths and limitations of this study
 ► This will be the first cluster- randomised controlled 
trial with a large sample size assessing the effica-
cy of calcium dobesilate (CaD) in treating diabetic 
retinopathy (DR) among individuals with mild- to- 
moderate non- proliferative DR.
 ► This study will collect longitudinal data on patients 
treated with CaD, and will report on the evolution of 
several important outcome measures over the first 
year.
 ► As with any longitudinal study, there is a risk of loss 
to follow- up throughout the study period, which may 
induce bias in the final results.
 ► A relatively short- term follow- up period of 12 
months might also be a limitation for this study.
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glycaemic control and laser therapy could not reverse the 
existing ocular damage and may only slow its progres-
sion. The safety of ocular surgery and its effectiveness 
in improving visual acuity have also been questioned.6 
Moreover, about three- quarters of the world’s diabetic 
patients live in low- income and middle- income countries 
with severely limited healthcare resources,7 which poses 
a serious challenge to the implementation of anti- VEGF 
therapy or surgical methods for DR.2 Therefore, access 
to affordable medicines, coupled with early detection of 
DR, may be a better way to prevent and delay diabetic 
blindness.1
Calcium dobesilate (CaD) is an angioprotective agent 
that has been proposed as a treatment for DR by protecting 
against retinal vascular damage.8 9 The earliest clinical 
study was a 2- year, double- blind, randomised controlled 
trial (RCT) involving 51 patients and 17 controls. The 
results showed that CaD was a potent angioprotector, 
which can prevent intra and extravascular haemorrhages 
of retina, reduce the incidence of exudate formation and 
improve visual acuity.10 A recent meta- analysis of eight 
RCTs consisting of 552 patients further demonstrated 
the angioprotective effects of CaD on the early stage of 
DR.11 However, other studies have reported that CaD had 
no beneficial effect on DR.12–15 One of them focused on 
the effect of CaD on the development of DME and was 
followed up for 5 years. This trial concluded that CaD 
did not reduce the risk of developing DME.14 Therefore, 
whether CaD is beneficial to DR is unclear.
The reason for the discrepancy between clinical 
trials is unknown. It should be noted that most of these 
studies generally have small sample size (range from 
18 to 194).10 12 13 15–21 The sample size of such studies is 
too small to draw any definitive conclusions. Although a 
most recent study with negative results included a rela-
tively large number of participants, however, the primary 
endpoint of that study was DME.14 As we all know, the 
first proven effective treatment for DME is macular laser 
photocoagulation or intravitreal injection of anti- VEGF 
agent,22 rather than CaD. Therefore, inconsistencies in 
the results of these studies may also be attributable to 
the inappropriate choice of primary endpoints. A review 
clearly identified the need for well- designed, robust 
trials.8 We aim to address these problems in the current 
study.
METHODS AND ANALYSIS
This study protocol was guided by the Standard Protocol 
Items: Recommendations for Interventional Trials 
reporting guidelines.23
Trial setting
The Efficacy of CALcium dobesilate in treating Chinese 
patients with Mild- to- moderate non- proliferative Diabetic 
Retinopathy (CALM- DR) is a multicentre randomised 
controlled study set in 24 tertiary hospitals in China. 
These centres are located in areas that spans the range 
of population densities, urbanisation and socioeconomic 
development status in China. We will recruit patients 
between June 2021 and December 2021. Follow- up will 
be completed in December 2022.
Rationale for using CaD
Despite of the inconsistent results of its efficacy, CaD still 
remains the only angioprotective agent that reduces the 
progression of DR.24 It was suggested in a review that 
some double- blind trials relating to permeability variables 
had better results with CaD than placebo, in particular 
a greater reduction in haemorrhage surface area and in 
fluorescein penetration into the vitreous body.25 Others 
showed an improvement of visual acuity after CaD treat-
ment.25 Another review showed that CaD had significantly 
superior effects on the evolution of BRB permeability 
compared with placebo.24 A recent meta- analysis indi-
cated that CaD could effectively treat DR at the systematic 
and local ocular levels compared with control.11
Safety
Safety profiles of CaD have been well established. Side 
effects are rare and uncommon with therapeutic doses 
of CaD. Uncommon side effect (0.1%–1%) is tachy-
cardia. Rare side effects (0.01%–0.1%) include nausea, 
diarrhoea, vomiting, rash, fever, chills, arthralgia, and 
agranulocytosis.
Hypotheses
In relation to the overall objective, the following are the 
hypotheses: (1) patients with diabetes who take CaD can 
reduce the progression of mild- to- moderate DR; (2) this 
intervention can also improve visual acuity and retinal 
vascular function of these patients.
Objectives
The primary objective of this study is to assess the poten-
tial therapeutic effect of CaD on the progression of mild- 
to- moderate DR in adults with diabetes. The secondary 
objective is to investigate the effect of the intervention 




The primary endpoint is the progression of DR during 12 
months after randomisation. After 12- month treatment, 
two digital fundus photographs will be taken for each eye 
according to Early Treatment Diabetic Retinopathy Study 
(ETDRS) scale standard of fundus photo description to 
evaluate the rate of improvement in the progression of 
patients with mild- to- moderate DR. DR progression is 
defined as an increase of two or more steps on the ETDRS 
scale during follow- up.26 The progression of mild- to- 
moderate DR has been widely used in some well- known 
clinical studies of DR, for example, Diabetes Control and 
Complications Trial (DCCT) study, Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) study and 
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Wisconsin Epidemiologic Study of Diabetic Retinopathy 
(WESDR) study.1
Secondary endpoints
1. Progression of DR from baseline to 3, 6 and 12 months.
2. Time from randomisation to the occurrence of pro-
gression of DR.
3. ETDRS scale at baseline to 3, 6 and 12 months.
4. Changes in eyesight postintervention from baseline to 
1, 3, 6 and 12 months/.
5. Changes in the numbers, location and types of the ret-
inal lesions postintervention from baseline to 3, 6 and 
12 months.
6. Changes in the retinal blood vessel diameter and arte-
riovenous ratio from baseline to 3, 6 and 12 months.
7. Changes in metabolic biomarkers such as HbA1c 
postintervention from baseline to 3, 6 and 12 months.
Additional repeat testing at 9 months is warranted for 
patient with type 1 diabetes.
Safety endpoints
1. Changes in physical examination and vital signs before 
and after treatment.
2. Changes in laboratory parameters (liver, renal func-
tion, blood routine, etc.).




1. Being diagnosed with mild- to- moderate DR.
2. Being older than 18 years.
3. Being willing to participate in the trial.
Exclusion criteria
1. Being allergic hypersensitive to experimental drugs 
or comparator drugs.
2. Having alanine aminotransferase or aspartate ami-
notransferase ≥2 times higher than the upper limit 
of normal value, or total bilirubin ≥1.5 times higher 
than the upper limit of normal value on the exclu-
sion of mild fatty liver disease.
3. Having severe renal insufficiency (defined as an 
eGFR ≤30 mL/min/1.73 m2).
4. Having malignant tumour and some other life- 
threatening diseases.
5. Being pregnancy, expecting pregnancy, or breast 
feeding.
6. Being with unstable conditions, such as: (1) uncon-
trolled high blood pressure (eg, BP>180/100 mm 
Hg); (2) glycosylated haemoglobin (HbA1c)>8.0% or 
uncontrolled high blood glucose or hypoglycaemic; 
(3) acute cardiovascular events like unstable angina, 
congestive heart failure, stroke, transient ischaemic 
attack or myocardial infarction within the previous 
3 months; (4) uncontrolled infection and (5) dia-
betic ketoacidosis or hyperosmolar state in the past 
1 month.
7. Being with glaucoma, cataracts or other opacities that 
may interfere with retinal examination and fundus 
photography.
8. Receiving drugs such as CaD or traditional Chinese 
medicine that may help to improve micro- vascular 
function in the past 2 weeks.
9. Receiving VEGF therapy in the past 4 months or will 
be judged to take VEGF therapy because of disease 
progression.
10. Having attended other clinical trials in the past 
1 month, being attending some clinical trials or some 
other conditions that are unfit for this trial judged by 
investigators.
Although the recruitment target is mainly middle- aged 
diabetic patients, the age standard is set at ≥18 years to 
include young patients with type 1 diabetes, because of 
the prevalence of DR in type 1 diabetes after an average 
of 23 years is 77%–95% despite adequate treatment for 
diabetes.27 The majority of exclusion criteria are based 
on reducing the risk of adverse effects associated with the 
intervention, as well as the rate of loss of follow- up.
Because some drugs (such as corticosteroids, non- 
steroidal anti- inflammatory drugs, antioxidants, inflam-
matory molecule inhibitors, renin–angiotensin system 
blockers and fenofibrate) may have an effect on DR,6 
patients who have used these medicines within 1 month 
will also be excluded.
Number and source of subjects
It is expected that approximately 1272 patients will be 
enrolled into the study from the 24 centres (hospitals) 
in China.
Screening procedures and prerandomisation investigations
The scope of our study presents a variety of potential 
barriers to participant recruitment, for which we will 
use an assortment of recruitment methods. Our recruit-
ment strategies will rely on community- level advertising, 
primary health service centre referrals and word- of- 
mouth recommendations of patients treated in centre 
in order to inform prospective participants of our study. 
Given that the focus of this study is on the treatment of 
DR, it is important to provide potential participants with 
an assessment of their retinopathy. We also ensure that 
participation in treatment conditions and data collection 
are convenient for the participants. A member of each 
centre research team will be in contact with people inter-
ested in participating in the study, screening for eligibility 
and explaining the main requirements for participa-
tion in the study. Written information will be sent to the 
potential participant who are eligible for participation. 
Researchers in each hospital will obtain informed consent 
signed by the participants.
No research- related procedures will be conducted until 
detailed written information about the study is provided 
to participants and informed consent is obtained. Those 
who are still interested in participating in this study 
after reading the materials will be invited to a health 
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examination (visit 0): (1) recording of lifestyle character-
istics, including smoking and alcohol; (2) recording of 
medical history, including glucose- lowering medications 
taken within the last 6 months and other prescription- only 
medications taking or have taken in the last month; (3) 
physical examination, including measurement of height, 
body weight, waist and hip circumferences and vital signs; 
(4) laboratory measurements of blood specimens and (5) 
a comprehensive eye examination (see below). Lifestyle 
education will also be provided.
Recruitment of patients will operate for 12 months in 
total in each centre.
Randomisation and masking
Extensive consultation has been conducted among clin-
ical stakeholders in each potential centre to ensure a will-
ingness to be randomised to one of two interventions and 
agreement to implement the allocated plan on a hospital 
wide level. Randomisation will be opened to participants 
and investigators for safety and practical considerations, 
but researchers related to participant’s identification, 
informed consent acquisition, enrolment and outcome 
evaluation will be blinded about the treatment allocation. 
24 hospitals will be randomised to the intervention and 
control arms on a 1:1 allocation ratio using a permuted- 
block randomisation method with block size of four. The 
allocation sequence will be generated using SAS PROC 
PLAN independent of the investigators, by the Global 
Health Trials Unit at the Liverpool School of Tropical 
Medicine (UK). This is achieved by the study team sharing 
a list of centres, each of which has a corresponding 
number. Allocation status will be communicated to the 
research team coordinator, who will inform respective 
centres after the investigators obtain the consents of the 
participants to participate in the trial. To ensure that all 
baseline measurements of allocated interventions by the 
investigators are unbiased, the allocation of the interven-




Participants allocated to the control group are requested 
not to alter their original lifestyle habits and treatment 
plan after randomisation and at the end of the study, 
with reviews by a study doctor and nurse. Management of 
blood glucose, blood pressure and lipid profiles is under-
taken by the study team during the period of the trial. 
Any changes to the treatment of these features are made 
by a doctor who unaware of treatment allocation to mini-
mise the risk of performance bias. During the period of 
this study, patients are treated as appropriate to maintain 
the following targets: HbA1c level <7.5%, blood pressure 
<140/80 mm Hg, total cholesterol level <4.0 mmol/L, 
triglyceride level <2.0 mmol/L, high- density lipopro-
tein level >1.0 mmol/L and low- density lipoprotein level 
<2.0 mmol/L (figure 1).
Treatment group
Patients in the treatment group will receive the same 
intervention as those in the control group. Additionally, 
participants will be asked to take a 1500 mg CaD per day 
in three divided doses of 500 mg for 1 year. The product 
will be delivered by the investigator at each centre.
Follow-up of patients
The duration of follow- up after randomisation is 12 
months. Patients will be seen at baseline and subse-
quently at months 3, 6 and 12 by the study team. We 
have included extra visits at 1 month to the patients’ 
routine schedule of visits. This extra visit is intended to 
re- enforce adherence to study drugs, to re- enforce their 
understanding of side effects and the actions that they 
need to take if these occur, and to examine the partici-
pant clinically.
Recording and monitoring of adverse events
Adverse events will be recorded by the attending physi-
cians and recorded details checked by an independent 
clinically qualified monitor.
Measures of adherence
Participants in CaD treatment will be asked to bring 
their study medication to visit 2 (month 1), visit 3 
(month 3), visit 4 (month 6) and visit 5 (month 12). The 
investigators will examine and register the amounts of 
tablets taken and thereby assess compliance to the drug. 
A compliance rate ≥80% is considered satisfactory.
Schedule for follow-up/flow chart
Eligible participants after screening will be included in 
the study (visit 1–visit 5) (table 1 and figure 1). Study 
visits are scheduled for the morning, after an overnight 
fast of ≥8 hour and omission of any morning doses of 
medications. As mentioned above, during the period of 
randomised treatments, visits are scheduled to occur at 
baseline and then after 1, 3, 6 and 12 months (±7 days). 
For those who are no longer receiving randomised treat-
ments, they are still scheduled to visit every 6 months, 
starting from the baseline visit.
At the baseline visit (visit 1), physical examination 
and blood sampling are repeated, and the following 
process are completed: (1) first- morning urine sample 
for measurement of urinary albumin/creatinine ratio; 
(2) visual acuity; (3) retinal photographs; (4) an exam-
ination of concomitant medications and (5) a review of 
current dietary and physical exercise.
Routine assessments to be performed when patients 
receive randomised treatment include: (1) complete 
physical examination; (2) laboratory test of fasting 
blood samples; (3) urinary albumin/creatinine ratio; 
(4) visual acuity; (5) retinal photographs; (6) recording 
of concomitant medications; (7) recording of adverse 
events and (8) a review of current dietary and physical 
exercise.
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Public and patient involvement
Patients and/or the public were not involved in the 
design, or conduct, or reporting, or dissemination 
plans of this research.
Implementation quality and intervention fidelity
To ensure both the quality and motivation, a series 
of dialogue meetings between project partners were 
held before and after recruitment of hospitals. Meet-
ings between the project and hospital leaderships, and 
the intervention implementers were held before and 
after recruitment, and regular meetings are planned 
throughout the study period. To ensure intervention 
fidelity, quarterly gatherings will be organised throughout 
the project period separately for the hospital leaderships 
and the study group members of each hospital to share 
experiences and motivate each other.
In each gathering, each hospital is required to develop 
an execution plan for their specific work the coming 
quarter. In addition, representatives from project lead-
erships will phone calls with each team every other week 
to discuss progress, challenges and solutions.
Assessments
Anthropometric
Height and body weight are measured in light indoor 
clothing without shoes. Height and weight are measured 
to the nearest 0.1 cm and 0.1 kg, respectively. Waist 
circumference, the mid- way between lowest rib and 
iliac crest, hip circumference and the level of the great 
trochanters, will be measured to the nearest 0.1 cm. 
Blood pressure measurements are taken after at least 
5 min of rest in duplicate separated by at least 5 min. 
The mean value of the two measurements will be used 
in the analysis. Subjects are required to refrain from 
smoking or ingesting caffeine for 30 min prior to the 
examination.
Figure 1 Treatment of patient flow chart. ACR, urinary albumin/creatinine ratio; BP, blood pressure; FPG, fasting plasma 
glucose; HbA1c, glycosylated haemoglobin; HDL, high- density lipoprotein; LDL, low- density lipoprotein; TC, total cholesterol, 
TG, triglyceride.
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Sociodemographic
Sociodemographic information, including age, gender, 
ethnicity, civil status, education, occupation, income, 
health history, smoking status and alcohol consumption, 
will be collected at baseline.
Fasting blood and first-morning urine samples
Fasting blood and first- morning urine samples will be 
collected and analysed for fasting plasma glucose, HbA1c, 
liver and renal functions, blood lipid profiles and urinary 
albumin/creatinine ratio at baseline and follow- up visits 
(table 1).
Visual acuity
Visual acuity will be measured in both eyes using ETDRS 
visual acuity charts at 4 m by optometrists at baseline and 
follow- up visits (table 1).
Retinal photographs
All persons with diabetes attending this study will undergo 
routine digital retinal photography, which is conducted 
in a darkened room using a non- mydriatic digital camera 
capturing optic disc and macular centred images per 
eye without the use of mydriasis by trained and certified 
photographers.
According to a grading protocol modified by Airlie 
House Classification system used in the Multi- Ethnic 
Study of Atherosclerosis, all retinal images from the 
patients will be independently reviewed and graded by 
one of three senior retinal graders who do not know 
the clinical details.28 Levels of DR are classified as no 
DR (levels 10–13) if no lesions are detected, and any 
DR (levels 14–80) when at least one microaneurysm 
and/or a blot haemorrhage are detected. DR is further 
divided into minimal- moderate NPDR (levels 14–20), 
mild–moderate NPDR (levels 31–41) and severe NPDR to 
proliferative retinopathy (levels 51–80). DME is defined 
as retinal thickening or hard exudates at least one disc 
diameter to the centre of the macular. Clinically signif-
icant macular oedema (CSME), introduced by ETDRS, 
is defined as DME meeting at least one of three criteria: 
thickening at or within 500 µm of the foveal centre, 
hard exudates within 500 µm of foveal centre with adja-
cent thickening or at least one disk diameter of thick-
ening with part of it located within one disc diameter of 
foveal centre. These are confirmed with central macular 
Table 1 Trial design, visits and end points
Visit Visit 0 Visit 1 Visit 2 Visit 3 Visit 4 Visit* Visit 5
Time (days from the start of 
intervention)




Height × × × × × × ×
Body weight × × × × × × ×
Waist circumference × × × × × × ×
Hip circumference × × × × × × ×
Blood pressure × × × × × × ×
Glycosylated haemoglobin × × × × × ×
Fasting plasma glucose × ×
Liver function × × × × × ×
Renal function × × × × × ×
Blood lipid profiles × × × × ×
Urinary albumin/creatinine ratio × × × × ×
Fasting blood samples × ×
Urine samples × ×
Visual acuity × × × × × ×
Retinal photographs × × × × × ×
Retinal vascular calibre × × × × ×
Adverse events × × × × ×
Drug accountability × × × × × ×
The maximum allowed time interval between screening (visit 0) and baseline examination (visit 1) will be 2 weeks (=14 days). Otherwise, 
a new screening will be conducted before the participants are included in the study.
*Additional visit at 9 months is warranted for patient with type 1 diabetes.
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thickness measurements by optical coherence tomog-
raphy using the macular thickness cube scan protocol. 
Vision- threatening retinopathy is defined as the presence 
of severe NPDR, proliferative retinopathy or CSME. The 
level of retinopathy is graded based on the worse eye. If 
an eye is ungradable, the score for the other eye will be 
used to define these outcomes.
Any discrepancies between the two initial graders will 
be adjudicated by a senior grader using standardised edit 
rules.
Retinal vascular calibr
Retinal vascular calibre is measured using a computer- 
based programme following a previously validated 
protocol.29 Optic disc- centred photographs of the right 
eye of each participant are measured. Left eye measure-
ments are performed when photographs of the right eye 
are ungradable. For each photograph, all arterioles and 
venules coursing through an area 0.5 to 1- disc diameter 
from the optic disc margin are measured and summarised 
as the average central arteriolar and venular equivalents. 
These equivalents represent the average of projected cali-
bres for the central retinal vessels, and have a high inter-
grader repeatability with intragrader and intergrader 
intraclass correlation coefficients ranging from 0.78 to 
0.99.30
Procedures for assessing safety
Throughout the course of the study, a steering committee 
meets to review progress every 6 months, and an inde-
pendent data safety monitoring board (DSMB) has been 
established to monitor safety and outcomes. The investi-
gators are responsible for ensuring that all serious adverse 
events are reported timely to the sponsor, who will then 
notify the ethics committee of the corresponding centres 
and the Chinese Medicines Agency according to the 
current laws and ICH/GCP guidelines. In case of unex-
pected severe adverse reactions to medication during 
the study, the trial will be discontinued. In addition, the 
DSMB may also recommend termination of the study for 
other serious safety reasons.
Subjects who withdraw from the study for any reason at 
any time will not be replaced. Subjects who are excluded 
or who decide to stop participating will be referred to 
their ophthalmologist for advice on how to manage 
their DR. At the end of the study, data on withdrawn 
subjects will be collected and used for efficacy and safety 
analyses.
Loss to follow-up
All subjects will be followed up for 12 months duration of 
the trial. Participants will be sent text message reminders 
prior to their appointment. If they fail to show, then they 
will be contacted by phone or by home visit if phoning is 
not possible to understand the reasons and reschedule 
another appointment within a week.
Trial closure
Study follow- up will be for 12 months following randomi-
sation. The trial will be considered closed after the last 
patient enrolled has completed 12 months of follow- up.
Withdrawal from trial intervention
Participants can withdraw from the intervention at any 
time. Participants may be withdrawn from the trial at the 
discretion of the investigator due to a safety concern or 
a serious violation of the protocol. Participants will be 
withdrawn in occurrence of pregnancy or at the inten-
tion to become pregnant. Withdrawn participants will 
be invited for the following assessments every 6 months 
unless written consent is withdrawn: (1) complete phys-
ical examination; (2) fasting blood specimens; (3) visual 
acuity; and (4) retinal photographs.
Statistical methods
Sample size
Progression of DR assessed by an increase of two or more 
steps on the ETDRS severity scale has not previously 
been used as primary outcome in RCTs of patients with 
DR treated with CaD. A prospective observational cohort 
study showed that with conventional treatment, the 
proportion of patients with two- step or greater progres-
sion of DR at 1 year was 15.2% (we contacted the study 
investigators to clarify the unpublished estimate).31 It is 
expected that combined medical therapy of DR in addi-
tion to conventional treatment will reduce the develop-
ment or progression of DR by approximately 50%.1 With 
a two- sided significance level of 5%, a power of 80% and 
an intracluster correlation coefficient of 0.01,32 a clini-
cally meaningful difference in the progression of DR over 
the 12- month intervention of ≥7.6% between two groups 
can be detected with 528 participants in each group. 
To allow for dropouts as 20%, we plan to include 1272 
subjects (636 in each of the two study groups), or 53 in 
each cluster.
Data management
Subjects will be identified by study ID. Study data will 
be collected and managed using the Smart CR secure 
web- based system33 developed by Suzhou MetroHealth 
Medical Technology, where electronic case report forms 
will be created. During the intervention phase, data will 
be entered directly into the Smart CR by study personnel 
and will be extracted by the investigators or sponsor. The 
fundus photograph data will be transmitted electronically 
from the person performing the operation to the same 
certified photographic grader and will be archived on a 
secure hard drive with backed up in Southeast University. 
All blood and urine samples obtained will be stored in a 
biobank for future use. Samples will be labelled with a 
unique study identifier.
All collected data will only be used for the purposes 
of the present study. Participants’ information will be 
confidential and anonymised and will only be treated at a 
collective level. Trial results will be shared with both the 
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scientific community and health professionals, through 
publications in scientific peer- reviewed journals and 
presentations at national and international conferences.
Statistical analysis
All statistical analyses will be performed using SAS V.9.4 
and Stata V.14 based on intention- to- treat principle 
and in accordance with the Consolidated Standards of 
Reporting Trials (CONSORT) guidelines for reporting 
cluster randomised trials. Per- protocol analysis will also 
be performed as supplementary analysis.
A generalised linear mixed- effects model (GLMMIX) 
will be fitted to analyse the primary endpoint. The model 
will have a binomial distribution and logit link function 
and include treatment, time and interaction between 
treatment and time as fixed factors; baseline ETDRS 
severity scale as covariate, and cluster and subject as 
random effects. OR with its 95% CI at each time point 
(3, 6 and 12 months) will be derived, which will also be 
converted into risk ratio using the mathematical relation-
ship between OR and risk ratio.34 A covariate- adjusted 
analysis of the primary endpoint will be performed by 
adding prespecified covariates at baseline into GLMMIX. 
Missing efficacy data will be treated as missing at random 
and no imputation will be made, because the GLMMIX 
model is a likelihood- based procedure and handles 
missing at random as ignorable.35 To evaluate the sensi-
tivity of the result of this assumption, the multiple impu-
tation method will be used to impute missing primary 
endpoint during follow- up. Prespecified subgroup anal-
yses are performed to explore the influence of covariates 
on primary endpoint.
For secondary binary outcomes, the similar GLMMIX 
will be used. For secondary continuous outcomes, the 
change from baseline for each of the outcomes will be 
modelled using GLMMIX with normal distribution and 
identity link function and with treatment, time and inter-
action between treatment and time as fixed factors, base-
line measurement as covariate, and cluster and subject as 
random effects. Mean difference and its 95% CI at each 
time point will be derived. Time- to- event outcome will 
be analysed using Cox proportional hazards regression 
model with frailty at the centre (cluster) level and treat-
ment as the study variable and intervention effects will be 
reported as HR with 95% CI. Kaplan- Meier plots will also 
be produced for the two study arms separately and log- 
rank test used to compare two time- to- event curves.
Detailed statistical analyses will be described in the 
statistical analysis plan, which will be developed and final-
ised before the database lockup.
ETHICS AND DISSEMINATION
The study is carried out in accordance with the Helsinki 
Declaration after approval by each local ethics committee 
(first Vote: Ethical Review Committees of Zhongda 
Hospital of Southeast University (2019ZDSYLL132- P01)).
CaD, which has been discovered more than 40 years ago 
and is registered for the treatment of DR in more than 
20 countries remains, to date, is the only angioprotec-
tive agent that reduces the progression of this disease.24 
Although CaD is effective in animal and/or in vitro 
models, however, the results of clinical trials are incon-
sistent. A large, multicentre study is warranted to provide 
a definitive conclusion.11 To the best of our knowledge, 
this study is the largest multicentre RCT, and is unique 
in embedding a cluster- randomised trial design within 
an intervention framework to study the effectiveness of 
CaD treatment on the progression of mild- to- moderate 
NPDR compared with conventional treatment. The effi-
cacy of the intervention on visual acuity, the presence, 
number, location and type of retinal lesions and retinal 
blood vessel diameter as well as arteriovenous ratio will 
also be tested. Our study will give us an opportunity to 
explore in depth whether CaD is beneficial for the treat-
ment of mild- to- moderate DR. A limitation of this study is 
the single- blinded study. Patients’ knowing of their treat-
ment groups may have a psychological impact on the trial 
results. However, the primary endpoint will be assessed 
by an independent committee and results regarding the 
primary endpoint will not be biased.
Even in the case of negative results, this trial will 
produce a large amount of illuminating data. Investiga-
tors will be able to closely monitor progression of DR in 
both arms during the 12- month follow- up period. If the 
treatment of CaD is effective, it will provide an additional 
therapy option for comprehensive management of the 
diabetic patients with mild- to- moderate DR.
The results of the trial will be analysed, presented 
and published as soon as possible at high- impact peer- 
reviewed journals and presented at the international 
scientific meetings and conferences. Manuscripts will be 
written in accordance with the CONSORT guidelines for 
reporting cluster randomised trials.
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